- Creation of Stallergenes by the Institut Mérieux, a world leader in vaccines

- Stallergenes enters the Benelux and North African markets.

- Stallergenes markets products in Germany

- Stallergenes develops and supplies one of the first anti-allergies vaccines to be administered orally.

- First NPP* automated production chain implemented by Stallergenes

- Merger of Stallergenes with the Allergen Division - Institut Pasteur

- Expansion of Stallergenes in Greece, Spain, Portugal and Turkey

- Acquisition of Stallergenes by Wendel Investissement

- Launch of Staloral^® (allergen immunotherapy by sublingual delivery)

- Creation of a subsidiary in Germany and purchase of a laboratory in Belgium

- Creation of a subsidiary in Italy and in Central Europe (Czech Republic and Slovakia)

- Establishment in Antony (Paris area)

- Introduction of Stallergenes to the Second Market of the Paris Stock Exchange

- With the purchase of DHS, the allergy division of Bayer Pharma, the Stallergenes-DHS Group becomes the world's number 2 company in its sector

- Opening of a subsidiary in Spain

- Awarded international ISO 9001 certification

- Pursuit of international development in South Africa, Australia, New Zealand and Poland.

- Stallergenes enters the Middle East markets

- Launch of Staloral 300^® (desensitisation therapy via sublingual drops) in Europe

- Initiation of the first clinical study comparing the efficacy of a recombinant allergen tablet to a current product

- Launch of a clinical study on the Grasses sublingual tablet, which represents a new therapeutic class and a significant advance for patients

- Acquisition of IPI's desensitization activity in Spain and Portugal
- Success of the clinical study on the Grasses tablet

- Subsidiary formation for promotional activity in the Czech Republic and in Slovakia

- Positive results from the first Proof of concept clinical study comparing the efficacy of a recombinant allergen (Bet v 1) with the current product based on a natural birch pollen extract.

- Results of the Phase I safety study of the Mites desensitisation tablet.

- Signature of an agreement for development and distribution of the desensitisation tablet with the Canadian company, Paladin Labs >>See the press release

- Development of a first product candidate as part of the Enhanced Allergens program with a view to pharmaceutical and preclinical development.

- Creation of a subsidiary in the Netherlands in partnership with the Dutch company SANMED B.V >> See the press release

- Commitment to the development and production of recombinant birch pollen and dust mites allergens (Partnerships with CMC and Protein'Expert)

- Positive results for the phase III clinical study of grass pollen induced rhino-conjunctivitis in chlidren (sublingual desensitisation tablet)

- Start of two clinicals studies a phase II/III for mite induced allergic rhinitis in adults (mites adult) in Europe ; a phase III for mite induced allergic asthma in adults (sublingual desensitisation drops treatment)

- Finalization of the construction of a new industrial unit on the Antony's site

- Achievement of the market authorization of the sublingual desensitisation tablet Oralair^® in Germany, serving as the reference country as part of the European mutual recognition procedure

See the press release